New screening guidelines for the prevention and early detection of cervical cancer are now largely based on the patient’s age, and testing for HPV DNA has now been incorporated into the screening process.
New screening guidelines for the prevention and early detection of cervical cancer are now largely based on the patient’s age, and testing for HPV DNA has now been incorporated into the screening process. The new recommendations are:
No screening before the age of 21.
Pap every 3 years from age 21 – 29, but no HPV screening.
Pap and HPV testing every 5 years from age 30 – 65.
Benefits to these new guidelines include: more time spent discussing BSE, referral for mammography, healthy diet and exercise, risky behaviors, family planning, menopausal transition, osteoporosis prevention, colorectal cancer screening, and evaluation of continence and pelvic floor functioning.
If you follow the new guidelines, will you encourage your patients to come in every year to discuss other health issues? We want to know, add your opinion to the comment box!
Assessing Onclarity HPV assay safety and efficacy for cervical cancer screening
February 21st 2024A recent study evaluated the safety and effectiveness of the Onclarity HPV assay in detecting high-grade cervical disease, presenting findings on its comparability to predicate assays and potential for cost-saving benefits in screening practices.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More